At six months, ADCTs provided greater pain relief and functional improvement than non-active controls, though no benefit was observed for quality-of-life. Severe adverse events were uncommon, but additional studies are needed for long-term efficacy and safety.
Madrazo-Ibarra et al. (Fri,) studied this question.